<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562624</url>
  </required_header>
  <id_info>
    <org_study_id>17700</org_study_id>
    <secondary_id>2018-000128-33</secondary_id>
    <nct_id>NCT03562624</nct_id>
  </id_info>
  <brief_title>A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components</brief_title>
  <acronym>INDessa</acronym>
  <official_title>Multi-center, Randomized, Comparator-controlled, Single-blind, Parallel-Group Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of an Intrauterine System (BAY987443) With Three Different Release Rates of Indomethacin and One Release Rate of Levonorgestrel, as Compared With Jaydess, in a Combined Proof-of-concept and Dose Finding Study in Healthy Pre-menopausal Women Treated for 90 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first study investigating the combined intrauterine administration of LNG
      (levonorgestrel) and IND (indomethacin). It is a combined proof-of-concept (PoC) and dose
      finding (DF) study in pre-menopausal women. It is designed to investigate the
      pharmacodynamics (PD) of BAY 987443 (i.e. IUS (intrauterine system) releasing LNG and IND),
      as well as pharmacokinetics (PK) of both active substances, safety and tolerability. In this
      study, Jaydess, as an LNG-only IUS, will be used as a comparator.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of uterine bleeding/spotting (B/S) days during treatment</measure>
    <time_frame>90 days after start of treatment</time_frame>
    <description>Recorded by participants with electronic diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects showing endometrial histology typical for intrauterine LNG application in biopsies taken at the end of treatment</measure>
    <time_frame>On day 90 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment emergent adverse events</measure>
    <time_frame>90 days after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>BAY98-7443 (low IND dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY98-7443 (middle IND dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combi IUS Treatment, LNG with medium dose of IND</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY98-7443 (high IND dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combi IUS Treatment, LNG with highest dose of IND</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed comparator IUS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY98-7443</intervention_name>
    <description>Active ingredient content (in mg IND/LNG):
low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5</description>
    <arm_group_label>BAY98-7443 (high IND dose)</arm_group_label>
    <arm_group_label>BAY98-7443 (low IND dose)</arm_group_label>
    <arm_group_label>BAY98-7443 (middle IND dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonogestrel (Skyla, BAY86-5028)</intervention_name>
    <description>Comparative LNG dose</description>
    <arm_group_label>Marketed comparator</arm_group_label>
    <other_name>Jaydess</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreement to use an acceptable non-hormonal method of contraception (i.e. male or
             female condom with or without spermicide; cap, diaphragm or sponge with spermicide)
             when sexually active. This applies during the pre-treatment cycle and directly
             following the treatment period until the end of the follow-up period. This is not
             required if safe contraception is achieved by a permanent method, such as bilateral
             fallopian tube blockage of the subject or vasectomy of the partner(s).

          -  Age at screening: 18-45 years inclusive

          -  Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m²

          -  No clinically relevant abnormal findings in the pre-treatment endometrial biopsy

          -  Adequate venous access (for frequent blood sampling)

        Exclusion Criteria:

          -  Menstrual disorders with unknown reason (not e.g. oligomenorrhea, hypomenorrhea
             amenorrhea due to hormonal treatment; not irregularities occurring during menarche).
             In case it is suspected that the woman is peri-menopausal, she should be excluded.

          -  Use of short-acting hormonal contraceptives/preparations containing sex hormones
             (oral, transdermal, intravaginal, IUS) during the pretreatment cycle

          -  Use of long-acting preparations containing sex hormones within the 40 weeks before the
             first screening examination (any long-acting injectable or implant)

          -  History of known or presence of suspected or known malignant tumors, especially any
             breast cancer, cervical carcinoma in situ or other progestin-sensitive cancer

          -  History of skin reactions, or other allergic-type reactions or known hypersensitivity
             reactions after taking aspirin, IND or other NSAIDs or to LNG, or any excipients of
             the IUSs

          -  Regular use of corticosteroids, irrespective of route of administration

          -  Known asthma bronchiale and aspirin-sensitive asthma

          -  Current or recurrent pelvic inflammatory disease

          -  Abnormal cervical smear within the last 6 month prior to screening

          -  Acute genital infection

          -  Known current thyroid disorders which require treatment (subjects with an euthyroid
             struma who do not need any treatment can participate)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenarztpraxis Dr. Wetzel</name>
      <address>
        <city>Blankenburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>38889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dinox GmbH Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRS Clinical Research Services Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC North GmbH &amp; Co. KG</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Hr. Dr. K. Peters</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL International Early Phase Clinical Unit (London)</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

